Lantern Pharma Advances Rare Pediatric Brain Cancer Treatment Using AI Platform

Lantern Pharma Inc. (NASDAQ: LTRN) is advancing clinical development for rare pediatric brain cancers using its proprietary computational biology and machine learning platform. The company is preparing to launch a clinical trial targeting a rare pediatric disease in Q1 2026 following constructive discussions with the U.S. Food and Drug Administration. The FDA provided critical guidance on trial design and regulatory pathways during a recent Type C meeting, reinforcing the company's approach to treating central nervous system cancers including Atypical Teratoid Rhabdoid Tumor.

The investigational therapy LP-184/STAR-001 represents a novel approach to combating these devastating childhood brain cancers. The treatment is designed to work synergistically with diuretic spironolactone and other potential combination regimens. Lantern's program for ATRT has received both Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, recognizing the significant unmet medical need in this area. The company is now preparing to submit an investigational new drug amendment to advance the clinical program.

Lantern President and CEO Panna Sharma expressed enthusiasm about the FDA feedback, noting that it highlights the potential of the company's AI platform, RADR, in identifying and optimizing combination regimens for pediatric CNS cancers. The RADR platform leverages over 200 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms to accelerate drug development. This AI-driven approach has enabled Lantern to advance new drug programs from initial insights to first-in-human clinical trials in just 2-3 years at approximately $2.5 million per program.

The company's progress in pediatric brain cancer treatment demonstrates how artificial intelligence is transforming oncology drug discovery and development. By harnessing computational power and machine learning, Lantern Pharma aims to address significant challenges in cancer treatment more efficiently and cost-effectively. The successful development of LP-184/STAR-001 could provide new therapeutic options for children suffering from rare and aggressive brain tumors where current treatment options remain limited.